BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, March 13, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

May 8, 2009

View Archived Issues

Vasopressin V2 receptor antagonist shows potential for treatment of ascites in cirrhotic patients

Read More

ITMN-191 and R-7128 combination reduces development of HCV resistance

Read More

Potent dual HCV/HIV replication inhibitors RO-0622, RO-9187 identified

Read More

Novel compounds for the treatment of pain discovered by Daiichi Sankyo

Read More

Researchers describe first bivalent humanized IgG1 antibody directed against human c-Met

Read More

Gene therapy Ad-IFNalpha/Syn3 safe and well tolerated in phase I study in bladder cancer

Read More

Topical AS-101 shows promise in treating psoriasis

Read More

Skin penetration of antifungal agents increased with the addition of NB-002

Read More

Novavax initiates enrollment in phase II clinical trial of VLP seasonal influenza vaccine

Read More

Replikins begins production of synthetic H1N1 swine flu vaccine

Read More

Merck initiates phase III SETTLE trial of safinamide in Parkinson's disease

Read More

AcelRx commences phase II clinical trial of ARX-01 Sufentanil NanoTab PCA System

Read More

Nymox begins enrollment into second phase III clinical trial of NX-1207 for BPH

Read More

Clavis reports preclinical data that differentiate CP-4200 from current standard cancer therapy

Read More

BioInvent reports phase I results for its therapeutic antibody BI-204

Read More

Anthera reports favorable results from phase II clinical trial of varespladib in ACS

Read More

Pierre Fabre initiates clinical trials of a pediatric beta-blocker for infantile hemangioma

Read More

D-Pharm submits IND and SPA to FDA for phase III trial of DP-b99 in acute stroke

Read More

Enzon establishes recommended dose of cancer drug PEG-SN38 for phase II studies

Read More

Intravitreal ARC-1905 combined with ranibizumab shows no toxicity in phase I trial

Read More

Pharmalucia claims novel compounds for the treatment of bacterial infections

Read More

Korea Research Institute of Chemical Technology describes novel inhibitors of ischemic cell death

Read More

Amsterdam Molecular treats first patient in preregistration clinical trial of Glybera

Read More

Oxygen Biotherapeutics files orphan drug application with FDA for Oxycyte

Read More

FDA grants priority review to Wyeth's BLA for pneumococcal vaccine Prevnar 13

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for March 13, 2026.
  • Tanycytes in green capturing tau protein in red.

    Brain’s hidden tau-clearing pathway uncovered

    BioWorld Science
    Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for March 10, 2026
  • MSD synthesizes α-synuclein PET agents

    BioWorld Science
    Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...
  • Muscarinic M4 receptor positive allosteric modulators described in Neurosterix patent

    BioWorld Science
    Neurosterix Pharma Sarl has divulged 3-cyclopropylpyrazole derivatives acting as muscarinic M4 receptor positive allosteric modulators. They are reported to be...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing